BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15733743)

  • 1. Potential regulatory role of the farnesoid X receptor in the metabolic syndrome.
    Duran-Sandoval D; Cariou B; Fruchart JC; Staels B
    Biochimie; 2005 Jan; 87(1):93-8. PubMed ID: 15733743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of bile acids and bile acid receptors in metabolic regulation.
    Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
    Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
    Claudel T; Staels B; Kuipers F
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2020-30. PubMed ID: 16037564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
    Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
    Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FXR: a promising target for the metabolic syndrome?
    Cariou B; Staels B
    Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FXR, a multipurpose nuclear receptor.
    Lee FY; Lee H; Hubbert ML; Edwards PA; Zhang Y
    Trends Biochem Sci; 2006 Oct; 31(10):572-80. PubMed ID: 16908160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FXR: a metabolic regulator and cell protector.
    Wang YD; Chen WD; Moore DD; Huang W
    Cell Res; 2008 Nov; 18(11):1087-95. PubMed ID: 18825165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
    Cariou B
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.
    Yang F; Huang X; Yi T; Yen Y; Moore DD; Huang W
    Cancer Res; 2007 Feb; 67(3):863-7. PubMed ID: 17283114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of carbohydrate metabolism by the farnesoid X receptor.
    Stayrook KR; Bramlett KS; Savkur RS; Ficorilli J; Cook T; Christe ME; Michael LF; Burris TP
    Endocrinology; 2005 Mar; 146(3):984-91. PubMed ID: 15564327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control.
    Kuipers F; Stroeve JH; Caron S; Staels B
    Curr Opin Lipidol; 2007 Jun; 18(3):289-97. PubMed ID: 17495603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders.
    Fiorucci S; Cipriani S; Baldelli F; Mencarelli A
    Prog Lipid Res; 2010 Apr; 49(2):171-85. PubMed ID: 19932133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus.
    Capello A; Moons LM; Van de Winkel A; Siersema PD; van Dekken H; Kuipers EJ; Kusters JG
    Am J Gastroenterol; 2008 Jun; 103(6):1510-6. PubMed ID: 18510604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR.
    Scholtes C; Diaz O; Icard V; Kaul A; Bartenschlager R; Lotteau V; André P
    J Hepatol; 2008 Feb; 48(2):192-9. PubMed ID: 18096266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
    Modica S; Moschetta A
    FEBS Lett; 2006 Oct; 580(23):5492-9. PubMed ID: 16904670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.
    Landrier JF; Eloranta JJ; Vavricka SR; Kullak-Ublick GA
    Am J Physiol Gastrointest Liver Physiol; 2006 Mar; 290(3):G476-85. PubMed ID: 16269519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
    Fujino T; Murakami K; Ozawa I; Minegishi Y; Kashimura R; Akita T; Saitou S; Atsumi T; Sato T; Ando K; Hara S; Kikugawa K; Hayakawa M
    FEBS J; 2009 Mar; 276(5):1319-32. PubMed ID: 19187229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor.
    Campana G; Pasini P; Roda A; Spampinato S
    Biochem Pharmacol; 2005 Jun; 69(12):1755-63. PubMed ID: 15935148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
    Martínez-Fernández P; Hierro L; Jara P; Alvarez L
    Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.